Rezera Announces Plans to Launch the REVEAL-PAD Multi-Center Study Investigating the Role of Inflammation in Patients with Peripheral Artery DiseaseAURORA, CO / ACCESS Newswire / September 22, 2026 / Rezera Inc. (the "Company"), a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3 to address inflammatory drivers of cardiovascular and neurologic diseases, announced plans to launch REVEAL-PAD, a prospective, multi-center observational study to investigate the role of inflammation in peripheral artery disease (PAD) and to identify patients who may be eligible to be screened for the Company's planned Phase 3 trial of ruvonoflast in PAD.
CPC Clinical Research Announces Dr. Connie Hess Receives Paul Dudley White Award For rNAPc2 in COVID 19 Presentation at the American Heart Association Vascular Discovery Scientific Sessions- Dr. Hess was selected as the recipient of an American Heart Association 2022 Paul Dudley White International Scholar Award, which is presented to the primary author of the highest ranked abstract submitted from each country to the conference. - Dr. Hess, Associate Professor of Medicine at the University of Colorado and a faculty member at CPC Clinical Research, presented results from the ASPEN-COVID-19 Phase 2b clinical trial evaluating rNAPc2
